NEW YORK (GenomeWeb News) – Intrexon announced after the close of the market on Tuesday the closing of its initial public offering raising $184 million in gross proceeds.

The Germantown, Md.-based synthetic biology firm said it sold about 11.5 million shares of its common stock at $16 per share. About 10 million shares were sold as part of the initial offering, and another 1.5 million shares were sold to the underwriters of the offering as part of their overallotment option.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: mtDNA analysis give glimpse into decline of Neanderthals in Europe, and more.

The University of Arizona's Raina Maier writes that an understanding of the Earth's microbiome is needed.

The proposed Canadian budget emphasizes partnerships with industry, Nature News reports.

An Australian study of personalized medicine has run into problems as it recruits patients.

Apr
29
Sponsored by
Covance

This online seminar will review case studies demonstrating the clinical utility of CTCs and cfDNA to define and characterize a variety of dynamic genomic changes throughout the course of cancer detection and treatment.